Processing Magazine

Pfizer wins Lipitor patent dispute in Denmark

August 29, 2008

Pfizer Inc. said Friday a court in Denmark has blocked Ranbaxy Laboratories from launching a generic version of the blockbuster cholesterol drug Lipitor in that country. Pfizer said a court in Copenhagen upheld two patents which were challenged by Ranbaxy Laboratories. The decision, which is subject to appeal, prevents Ranbaxy from launching a cheaper, generic version of Lipitor before 2011, when Pfizer''s patents expire. Lipitor is the world''s best-selling drug, generating nearly $13 billion in 2007 sales. Indian generic drug maker Ranbaxy is battling Pfizer over the drug in half a dozen countries, including Spain, Portugal and Finland. In June, Pfizer and Ranbaxy settled their patent dispute over Lipitor in the U.S. and several other countries in Europe and Asia. Under the agreement, Ranbaxy will be able to launch generic Lipitor in those countries starting November 2011 the Associated Press reports.